Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck

Naomi Kiyota,Makoto Tahara,Akihiro Homma

DOI: https://doi.org/10.1093/jjco/hyae029

IF: 2.925

2024-03-07

Japanese Journal of Clinical Oncology

Abstract:Abstract Surgery remains a foundation of treatment for locally advanced squamous cell carcinoma of the head and neck. For postoperative patients at high risk of recurrence, however, surgery by itself is not enough, and improvement in survival requires postoperative treatment. Unlike the case with most other malignancies, the standard postoperative treatment for locally advanced squamous cell carcinoma of the head and neck patients with high-risk factors for recurrence is radiotherapy or chemoradiotherapy with cisplatin. However, chemoradiotherapy with cisplatin at a dose of 100 mg/m2 once every 3 weeks has raised discussion over insufficient cisplatin delivery due to high-dose-related toxicity. As a possible solution, a recent randomized trial of the JCOG1008 has proved the non-inferiority of postoperative chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 to 3-weekly cisplatin in terms of overall survival. Here, this review article focuses on current evidence and future perspectives of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.

oncology

What problem does this paper attempt to address?

This paper aims to explore the current situation and future directions of postoperative treatment for locally advanced head and neck squamous cell carcinoma (SCCHN). Specifically, the article focuses on how to improve the survival rate of patients with high recurrence risk by optimizing postoperative radiotherapy or chemotherapy regimens while reducing the toxic and side effects of treatment. The current standard treatment regimen is postoperative chemoradiotherapy with cisplatin, but the toxicity of high - dose cisplatin (100 mg/m², once every 3 weeks) limits its application. Therefore, researchers are exploring the effectiveness and safety of cisplatin regimens with lower doses and more frequent administration (such as 40 mg/m² per week), as well as other alternative drugs (such as carboplatin, cetuximab, etc.). In addition, immunotherapy, as a new treatment method, is also being evaluated for its ability to further improve the prognosis of patients.

The paper also discusses the possibility of reducing the treatment intensity for HPV - positive oropharyngeal cancer patients, as well as a number of ongoing clinical trials. These trials aim to evaluate new adjuvant treatment strategies, such as adding EGFR inhibitors (nimotuzumab), IAP inhibitors (Xevinapant), PD - 1/PD - L1 inhibitors (atezolizumab, pembrolizumab, etc.), in order to find more effective and less toxic treatment regimens.